


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:


1. (Currently Amended) A composition for cancer treatment comprising a compound represented by formula 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer:



wherein, R¹ is propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl grouphydrogen or a-substituted or unsubstituted C₁-C₂₀ alkylcarbonyl group.

2.-3. (Cancelled)


4. (Currently Amended) A composition for the enhancement of radiosensitizing effect comprising a compound represented by formula 1 or a pharmaceutically acceptable salt:



wherein, R¹ is propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl grouphydrogen or a substituted or unsubstituted C₁-C₂₀ alkylcarbonyl group.

5.-6. (Cancelled)

7. (New) A method for treating a cancer comprising administering to a human in need of treatment a therapeutically effective amount of a compound represented by formula 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from a group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer:




wherein, R¹ is hydrogen or a substituted or unsubstituted C₁-C₂₀ alkylcarbonyl group.

8. (New) The method according to claim 7, wherein R^1 is hydrogen, ethanoyl group, propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.

9. (New) The method according to claim 7, wherein R^1 is hydrogen, butanoyl group, hexanoyl group, or octanoyl group.

10. (New) A method for enhancing radiosensitizing effect comprising administering to a human in need of treatment a therapeutically effective amount of a compound represented by formula 1 or a pharmaceutically acceptable salt:



wherein, R^1 is hydrogen or a substituted or unsubstituted C_1 - C_{20} alkylcarbonyl group.

11. (New) The method according to claim 10, wherein R^1 is hydrogen, ethanoyl group, propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.

12. (New) The method according to claim 10, wherein R^1 is hydrogen, butanoyl group, hexanoyl group, or octanoyl group.